Abstract
1. The pharmacodynamics of the dopamine DA1 agonist fenoldopam were examined in six healthy male volunteers after constant intragastric infusions of fenoldopam at dosages of 0, 10, 25, 50 and 75 mg h-1 for 6 h. 2. Hourly p-aminohippurate (PAH) clearance was used to assess fenoldopam induced renal plasma flow changes. Marked dose-related increases in renal plasma flow were noted with a maximal increase of 65% over baseline values of 711 ml min-1 being seen at the 75 mg h-1 rate. No changes in sodium excretion and glomerular filtration rate were observed. 3. Mean steady-state fenoldopam plasma concentrations were related to mean PAH clearance based on an Emax model (r = 0.996) with an Emax of 1350 ml min-1 and an EC50 of 6.2 ng ml-1. 4. Mean steady-state plasma concentrations of fenoldopam-7-sulphate and fenoldopam-8-sulphate failed to increase with dose but were linearly correlated to mean PAH changes (r = 0.998, r = 0.981 respectively). 5. These results support the concept of extending fenoldopam's duration of action through the development of an oral sustained delivery system.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boppana V. K., Heineman F. C., Lynn R. K., Randolph W. C., Ziemniak J. A. Determination of fenoldopam (SK&F 82526) and its metabolites in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1984 Dec 28;317:463–474. doi: 10.1016/s0021-9673(01)91686-3. [DOI] [PubMed] [Google Scholar]
- Harvey J. N., Worth D. P., Brown J., Lee M. R. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol. 1985 Jan;19(1):21–27. doi: 10.1111/j.1365-2125.1985.tb02608.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Holford N. H., Sheiner L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429–453. doi: 10.2165/00003088-198106060-00002. [DOI] [PubMed] [Google Scholar]
- Levy G., Matsuzawa T. Pharmacokinetics of salicylamide elimination in man. J Pharmacol Exp Ther. 1967 May;156(2):285–293. [PubMed] [Google Scholar]
- Levy G., Yamada H. Drug biotransformation interactions in man. 3. Acetaminophen and salicylamide. J Pharm Sci. 1971 Feb;60(2):215–221. doi: 10.1002/jps.2600600212. [DOI] [PubMed] [Google Scholar]
- Stoof J. C., Kebabian J. W. Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 1984 Dec 3;35(23):2281–2296. doi: 10.1016/0024-3205(84)90519-8. [DOI] [PubMed] [Google Scholar]
- Stote R. M., Dubb J. W., Familiar R. G., Erb B. B., Alexander F. A new oral renal vasodilator, fenoldopam. Clin Pharmacol Ther. 1983 Sep;34(3):309–315. doi: 10.1038/clpt.1983.173. [DOI] [PubMed] [Google Scholar]
- Yeh B. K., McNay J. L., Goldberg L. I. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther. 1969 Aug;168(2):303–309. [PubMed] [Google Scholar]
- Young J. B., Leon C. A., Pratt C. M., Suarez J. M., Aronoff R. D., Roberts R. Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. J Am Coll Cardiol. 1985 Oct;6(4):792–796. doi: 10.1016/s0735-1097(85)80484-8. [DOI] [PubMed] [Google Scholar]
- Ziemniak J. A., Allison N., Boppana V. K., Dubb J., Stote R. The effect of acetaminophen on the disposition of fenoldopam: competition for sulfation. Clin Pharmacol Ther. 1987 Mar;41(3):275–281. doi: 10.1038/clpt.1987.28. [DOI] [PubMed] [Google Scholar]